Last 702.60 INR
Change Today -6.60 / -0.93%
Volume 915.3K
RBXY On Other Exchanges
Symbol
Exchange
Natl India
OTC US
OTC US
As of 6:06 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

ranbaxy laboratories ltd (RBXY) Snapshot

Open
709.20
Previous Close
709.20
Day High
714.00
Day Low
694.80
52 Week High
01/28/15 - 725.00
52 Week Low
02/4/14 - 307.50
Market Cap
299.1B
Average Volume 10 Days
1.1M
EPS TTM
--
Shares Outstanding
425.7M
EX-Date
04/28/11
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RANBAXY LABORATORIES LTD (RBXY)

Related News

No related news articles were found.

ranbaxy laboratories ltd (RBXY) Related Businessweek News

View More BusinessWeek News

ranbaxy laboratories ltd (RBXY) Details

Ranbaxy Laboratories Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical products. The company offers generics, differentiated products, over-the-counter products, anti-retrovirals, active pharmaceutical ingredients, and intermediates. Its products are used for the treatment in various therapy areas, including anti-infectives, cardiovascular, pain and musculoskeletal, central nervous system, gastrointestinal, respiratory, anti-retrovirals, dermatology, orthopaedics, nutritionals, urology, and diabetes. The company offers a portfolio of approximately 500 molecules in the forms of tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Ranbaxy Laboratories Limited operates in India, Europe, North America, the Asia Pacific, and Africa. The company was founded in 1961 and is headquartered in New Delhi, India. Ranbaxy Laboratories Limited is a subsidiary of Daiichi Sankyo Company, Ltd.

15,300 Employees
Last Reported Date: 07/1/14
Founded in 1961

ranbaxy laboratories ltd (RBXY) Top Compensated Officers

Chief Executive Officer, Managing Director, E...
Total Annual Compensation: 122.7M
Compensation as of Fiscal Year 2014.

ranbaxy laboratories ltd (RBXY) Key Developments

Ranbaxy Laboratories Ltd. Reports Unaudited Consolidated and Standalone Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Ranbaxy Laboratories Ltd. reported unaudited consolidated and standalone financial results for the fourth quarter and year ended December 31, 2014. For the quarter, on consolidated basis, the company’s total income from operations (net) was INR 26,188.46 million against INR 28,939.92 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 161.24 million against INR 1,788.42 million a year ago. Loss from ordinary activities before tax was INR 1,354.13 million against INR 603.49 million a year ago. Net loss for the period was INR 10,236.05 million against INR 1,584.89 million a year ago. Diluted loss per share was INR 24.26 against INR 3.76 a year ago. Sales were INR 25,876 million against INR 28,590 million a year ago. Earnings before interest, tax, depreciation & amortization (EBITDA) were INR 1,129 million. For the full year, standalone total income from operations (net) was INR 82,953.66 million against INR 83,298.30 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 8,517.77 million against INR 3,679.16 million a year ago. Profit from ordinary activities before tax was INR 2,354.32 million against loss from ordinary activities before tax of INR 9,384.00 million a year ago. Net loss for the period was INR 7,323.11 million against INR 11,246.46 million a year ago. Diluted loss per share was INR 17.41 against INR 26.89 a year ago. Sales were INR 81,778 million against INR 81,931 million a year ago. Earnings before interest, tax, depreciation & amortization (EBITDA) was INR 11,579 million. For the quarter, on standalone basis, the company’s total income from operations (net) was INR 10,098.49 million against INR 13,665.63 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 4,063.15 million against INR 1,118.96 million a year ago. Loss from ordinary activities before tax was INR 5,651.35 million against INR 3,959.60 million a year ago. Net loss for the period was INR 14,204.85 million against INR 3,959.60 million a year ago. Diluted loss per share was INR 33.47 against INR 9.36 a year ago. For the full year, on standalone basis, the company’s total income from operations (net) was INR 44,971.58 million against INR 42,312.84 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 2,386.94 million against loss from operations before other income, finance costs and exceptional items of INR 5,035.98 million a year ago. Loss from ordinary activities before tax was INR 1,690.32 million against INR 18,470.01 million a year ago. Net loss for the period was INR 10,336.19 million against INR 18,470.01 million a year ago. Diluted loss per share was INR 24.38 against INR 43.67 a year ago.

Ranbaxy Announces Launch of Anti-Malarial Drug in African Countries

Ranbaxy Laboratories Ltd. has received the regulatory approval to launch new chemical entity, or NCE, Synriam, an anti-malarial drug, in seven African countries namely Nigeria, Uganda, Senegal, Cameroon Guinea, Kenya and Ivory Coast. The product has since been launched in Uganda and will be made available in other countries towards end of January 2015.

Ranbaxy Laboratories Ltd., Board Meeting, Jan 28, 2015

Ranbaxy Laboratories Ltd., Board Meeting, Jan 28, 2015. Agenda: To approve standalone and consolidated unaudited financial results for the third quarter and nine months ending December 31, 2014 as reviewed by the statutory auditors of the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RBXY:IN 702.60 INR -6.60

RBXY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RBXY.
View Industry Companies
 

Industry Analysis

RBXY

Industry Average

Valuation RBXY Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RANBAXY LABORATORIES LTD, please visit www.ranbaxy.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.